{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:41:27Z","timestamp":1787726487655,"version":"build-2784847793"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP17dm0107071"],"award-info":[{"award-number":["JP17dm0107071"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP18dm0107071"],"award-info":[{"award-number":["JP18dm0107071"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["18J20651"],"award-info":[{"award-number":["18J20651"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.neuropharm.2019.03.029","type":"journal-article","created":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T12:38:06Z","timestamp":1553776686000},"page":"164-174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Inhibition of MPTP-induced \u03b1-synuclein oligomerization by fatty acid-binding protein 3 ligand in MPTP-treated mice"],"prefix":"10.1016","volume":"150","author":[{"given":"Kazuya","family":"Matsuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Yabuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibuki","family":"Takahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Miyachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohji","family":"Fukunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2019.03.029_bib1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0896-6273(00)80886-7","article-title":"Mice lacking \u03b1-synuclein display functional deficits in the nigrostriatal dopamine system","volume":"25","author":"Abeliovich","year":"2000","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2019.03.029_bib2","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2019.03.029_bib3","doi-asserted-by":"crossref","first-page":"29739","DOI":"10.1074\/jbc.M600933200","article-title":"Phosphorylation of Ser-129 is the dominant pathological modification of \u03b1-synuclein in familial and sporadic lewy body disease","volume":"281","author":"Anderson","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.03.029_bib4","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.bmcl.2009.01.084","article-title":"N-Benzyl-indolo carboxylic acids: design and synthesis of potent and selective adipocyte fatty-acid binding protein (A-FABP) inhibitors","volume":"19","author":"Barf","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.neuropharm.2019.03.029_bib5","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1002\/pmic.200400848","article-title":"Proteome analysis of human substantia nigra in Parkinson's disease","volume":"4","author":"Basso","year":"2004","journal-title":"Proteomics"},{"key":"10.1016\/j.neuropharm.2019.03.029_bib6","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/j.bmcl.2013.01.054","article-title":"Structure-guided design, synthesis and in vitro evaluation of a series of pyrazole-based fatty acid binding protein (FABP) 3 ligands","volume":"23","author":"Beniyama","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.neuropharm.2019.03.029_bib7","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00702-002-0808-2","article-title":"Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen","volume":"110","author":"Braak","year":"2003","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.neuropharm.2019.03.029_bib8","doi-asserted-by":"crossref","first-page":"15610","DOI":"10.1021\/bi061743l","article-title":"\u03b1-Synuclein adopts an \u03b1-helical conformation in the presence of polyunsaturated fatty acids to hinder micelle formation","volume":"45","author":"Broersen","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.neuropharm.2019.03.029_bib9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ejmech.2014.11.020","article-title":"Novel fatty acid binding protein 4 (FABP4) inhibitors: virtual screening, synthesis and crystal structure determination","volume":"90","author":"Cai","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2019.03.029_bib10","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/nn1443","article-title":"\u03b1-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease","volume":"8","author":"Chen","year":"2005","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.03.029_bib11","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.brainres.2018.11.036","article-title":"Development of FABP3 ligands that inhibit arachidonic acid-induced \u03b1-synuclein oligomerization","volume":"1707","author":"Cheng","year":"2019","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2019.03.029_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/S0005-2760(97)00205-1","article-title":"Physiological properties and functions of intracellular fatty acid-binding proteins","author":"Coe","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neuropharm.2019.03.029_bib13","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1126\/science.1063522","article-title":"Kinetic stabilization of the \u03b1-synuclein protofibril by a dopamine-\u03b1-synuclein adduct","volume":"294","author":"Conway","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2019.03.029_bib14","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1093\/cercor\/11.12.1136","article-title":"Enhanced or impaired cognitive function in Parkinson's Disease as a function of dopaminergic medication and task demands","volume":"11","author":"Cools","year":"2001","journal-title":"Cerebr. Cortex"},{"key":"10.1016\/j.neuropharm.2019.03.029_bib15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000067968","article-title":"Dopaminergic modulation of visual-spatial working memory in Parkinson's disease","volume":"15","author":"Costa","year":"2003","journal-title":"Dement. Geriatr. Cognit. Disord."},{"key":"10.1016\/j.neuropharm.2019.03.029_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(09)70238-8","article-title":"Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria","author":"Dickson","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2019.03.029_bib17","doi-asserted-by":"crossref","first-page":"10209","DOI":"10.1021\/bi020139h","article-title":"Annular \u03b1-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes","volume":"41","author":"Ding","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.neuropharm.2019.03.029_bib18","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.neuropsychologia.2009.12.039","article-title":"Effect of disease severity and dopaminergic medication on recollection and familiarity in patients with idiopathic nondementing Parkinson's","volume":"48","author":"Edelstyn","year":"2010","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.neuropharm.2019.03.029_bib19","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archneur.56.5.529","article-title":"Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA","volume":"56","author":"Fahn","year":"1999","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2019.03.029_bib20","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/ncb748","article-title":"\u03b1-synuclein is phosphorylated in synucleinopathy lesions","volume":"4","author":"Fujiwara","year":"2002","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.neuropharm.2019.03.029_bib21","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/nature05844","article-title":"Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2","volume":"447","author":"Furuhashi","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2019.03.029_bib22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0006-8993(94)90512-6","article-title":"Mesolimbic dopaminergic neurons innervating the hippocampal formation in the rat: a combined retrograde tracing and immunohistochemical study","volume":"668","author":"Gasbarri","year":"1994","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2019.03.029_bib23","doi-asserted-by":"crossref","first-page":"6956","DOI":"10.1021\/bi0600289","article-title":"Acyl-CoA synthetase activity links wild-type but not mutant \u03b1-synuclein to brain arachidonate metabolism","volume":"45","author":"Golovko","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.neuropharm.2019.03.029_bib24","doi-asserted-by":"crossref","DOI":"10.1023\/A:1020502624234","article-title":"Insights into binding of fatty acids by fatty acid binding proteins","author":"Hanhoff","year":"2002","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.neuropharm.2019.03.029_bib25","doi-asserted-by":"crossref","first-page":"33928","DOI":"10.1038\/srep33928","article-title":"Arachidonic acid mediates the formation of abundant alpha-helical multimers of alpha-synuclein","volume":"6","author":"Iljina","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2019.03.029_bib26","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1111\/j.1742-4658.2011.08093.x","article-title":"Modulation of \u03b1-synuclein aggregation by dopamine in the presence of MPTP and its metabolite","volume":"278","author":"Jethva","year":"2011","journal-title":"FEBS J."},{"key":"10.1016\/j.neuropharm.2019.03.029_bib27","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1016\/j.febslet.2008.10.001","article-title":"N-terminal region of \u03b1-synuclein is essential for the fatty acid-induced oligomerization of the molecules","volume":"582","author":"Karube","year":"2008","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neuropharm.2019.03.029_bib28","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1001\/archneur.65.12.1577","article-title":"Central role of alpha-synuclein oligomers in neurodegeneration in Parkinson disease","volume":"65","author":"Kazantsev","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2019.03.029_bib29","doi-asserted-by":"crossref","first-page":"10931","DOI":"10.1073\/pnas.0402342101","article-title":"Effects of dietary omega-3 polyunsaturated fatty acids on brain gene expression","volume":"101","author":"Kitajka","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.neuropharm.2019.03.029_bib30","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00001756-200001170-00041","article-title":"MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons","volume":"11","author":"Kowall","year":"2000","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2019.03.029_bib31","doi-asserted-by":"crossref","first-page":"E4648","DOI":"10.1073\/pnas.1704698114","article-title":"Selective lowering of synapsins induced by oligomeric \u03b1-synuclein exacerbates memory deficits","volume":"114","author":"Larson","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.neuropharm.2019.03.029_bib32","article-title":"Improved immunodetection of endogenous\u202f\u03b1-synuclein","volume":"6","author":"Lee","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2019.03.029_bib33","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.freeradbiomed.2009.02.009","article-title":"Formation of dopamine-mediated \u03b1-synuclein-soluble oligomers requires methionine oxidation","volume":"46","author":"Leong","year":"2009","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.neuropharm.2019.03.029_bib34","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.freeradbiomed.2014.05.022","article-title":"Polo-like kinase 2 activates an antioxidant pathway to promote the survival of cells with mitochondrial dysfunction","volume":"73","author":"Li","year":"2014","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.neuropharm.2019.03.029_bib35","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/jmcb\/mjr011","article-title":"A novel molecular mechanism for nitrated \u03b1-synuclein-induced cell death","volume":"3","author":"Liu","year":"2011","journal-title":"J. Mol. Cell Biol."},{"key":"10.1016\/j.neuropharm.2019.03.029_bib36","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1734-1140(11)70606-5","article-title":"Buspirone improves the anti-cataleptic effect of levodopa in 6-hydroxydopamine-lesioned rats","volume":"63","author":"Mahmoudi","year":"2011","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.neuropharm.2019.03.029_bib37","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1074\/jbc.C100560200","article-title":"The herbicide paraquat causes up-regulation and aggregation of\u202f\u03b1-synuclein in mice: paraquat and\u202f\u03b1-synuclein","volume":"277","author":"Manning-Bog","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.03.029_bib38","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0140-6736(76)91416-1","article-title":"\u201cOn-off\u201d effects in patients with Parkinson's disease on chronic levodopa therapy","volume":"1","author":"Marsden","year":"1976","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2019.03.029_bib39","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(77)91146-1","article-title":"Success and problems of long-term levodopa therapy in parkinson\u2019s disease","volume":"1","author":"Marsden","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2019.03.029_bib40","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.brainres.2017.03.014","article-title":"Combined L-citrulline and glutathione administration prevents neuronal cell death following transient brain ischemia","volume":"1663","author":"Matsuo","year":"2017","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2019.03.029_bib41","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jns.2009.09.021","article-title":"Dietary fat intake and risk of Parkinson's disease: a case-control study in Japan","volume":"288","author":"Miyake","year":"2010","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2019.03.029_bib42","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1471-4159.2011.07608.x","article-title":"Reduced calcium\/calmodulin-dependent protein kinase II activity in the hippocampus is associated with impaired cognitive function in MPTP-treated mice","volume":"120","author":"Moriguchi","year":"2012","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2019.03.029_bib43","doi-asserted-by":"crossref","first-page":"6350","DOI":"10.1021\/bi047292r","article-title":"Brain arachidonic acid incorporation is decreased in heart fatty acid binding protein gene-ablated mice","volume":"44","author":"Murphy","year":"2005","journal-title":"Biochemistry"},{"key":"10.1016\/j.neuropharm.2019.03.029_bib44","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.neuropharm.2008.11.004","article-title":"Behavioural and neurochemical response of \u03b1-synuclein A30P transgenic mice to the effects of L-DOPA","volume":"56","author":"Oksman","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.03.029_bib45","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0891-0618(96)00192-5","article-title":"Spatio-temporally differential expression of genes for three members of fatty acid binding proteins in developing and mature rat brains","volume":"12","author":"Owada","year":"1996","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.neuropharm.2019.03.029_bib46","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.nbd.2015.06.003","article-title":"Intrastriatal injection of pre-formed mouse \u03b1-synuclein fibrils into rats triggers \u03b1-synuclein pathology and bilateral nigrostriatal degeneration","volume":"82","author":"Paumier","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2019.03.029_bib47","series-title":"The Mouse Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2001"},{"key":"10.1016\/j.neuropharm.2019.03.029_bib48","doi-asserted-by":"crossref","first-page":"41958","DOI":"10.1074\/jbc.M105022200","article-title":"Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins","volume":"276","author":"Perrin","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.03.029_bib49","doi-asserted-by":"crossref","first-page":"5862","DOI":"10.1074\/jbc.M608126200","article-title":"Effect of 4-hydroxy-2-nonenal modification on\u202f\u03b1-synuclein aggregation","volume":"282","author":"Qin","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.03.029_bib50","doi-asserted-by":"crossref","first-page":"9110","DOI":"10.1073\/pnas.171300598","article-title":"Alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins","volume":"98","author":"Sharon","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.neuropharm.2019.03.029_bib51","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0896-6273(03)00024-2","article-title":"The formation of highly soluble oligomers of \u03b1-synuclein is regulated by fatty acids and enhanced in Parkinson's disease","volume":"37","author":"Sharon","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2019.03.029_bib52","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1523\/JNEUROSCI.4140-09.2010","article-title":"Heart-type fatty acid binding protein regulates dopamine D2 receptor function in mouse brain","volume":"30","author":"Shioda","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.03.029_bib53","doi-asserted-by":"crossref","first-page":"18957","DOI":"10.1074\/jbc.M113.527341","article-title":"FABP3 protein promotes \u03b1-synuclein oligomerization associated with 1-Methyl-1,2,3,6-tetrahydropiridine-induced neurotoxicity","volume":"289","author":"Shioda","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.03.029_bib54","article-title":"Targeted overexpression of \u03b1-synuclein by rAAV2\/1 vectors induces progressive nigrostriatal degeneration and increases vulnerability to MPTP in mouse","volume":"10","author":"Song","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2019.03.029_bib55","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"alpha-Synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2019.03.029_bib56","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/j.1460-9568.2007.05736.x","article-title":"Oxidative stress-induced phosphorylation, degradation and aggregation of \u03b1-synuclein are linked to upregulated CK2 and cathepsin D","volume":"26","author":"Takahashi","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.03.029_bib57","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1073\/pnas.1100976108","article-title":"In vivo demonstration that \u03b1-synuclein oligomers are toxic","volume":"108","author":"Winner","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.neuropharm.2019.03.029_bib58","doi-asserted-by":"crossref","first-page":"34272","DOI":"10.1074\/jbc.M109.049809","article-title":"Fibril fragmentation enhances amyloid cytotoxicity","volume":"284","author":"Xue","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.03.029_bib59","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.neuroscience.2013.11.051","article-title":"Nobiletin treatment improves motor and cognitive deficits seen in MPTP-induced Parkinson model mice","volume":"259","author":"Yabuki","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2019.03.029_bib60","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jchemneu.2017.07.002","article-title":"Role of estrogen and levodopa in 1-methyl-4-pheny-l-1, 2, 3, 6-tetrahydropyridine (mptp)-induced cognitive deficit in Parkinsonian ovariectomized mice model: a comparative study","volume":"85","author":"Yadav","year":"2017","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.neuropharm.2019.03.029_bib61","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00401-011-0815-1","article-title":"Changes in the solubility and phosphorylation of \u03b1-synuclein over the course of Parkinson's disease","volume":"121","author":"Zhou","year":"2011","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuropharm.2019.03.029_bib62","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.taap.2011.05.007","article-title":"MPTP-meditated hippocampal dopamine deprivation modulates synaptic transmission and activity-dependent synaptic plasticity","volume":"254","author":"Zhu","year":"2011","journal-title":"Toxicol. Appl. Pharmacol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081930108X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081930108X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T06:54:25Z","timestamp":1758437665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839081930108X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":62,"alternative-id":["S002839081930108X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.03.029","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of MPTP-induced \u03b1-synuclein oligomerization by fatty acid-binding protein 3 ligand in MPTP-treated mice","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.03.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}